Bayer wins FDA ok for hemophilia drug

Aug 30, 2018

Bayer AG has received U.S. FDA approval for a Factor VIII hemophilia drug, called Jivi.

Jivi is used in preventative treatment of hemophilia A and is also approved for on-demand treatment. It is the third FDA-approved hemophilia A treatment in Bayer’s hemophilia portfolio.

Bayer has also submitted marketing authorization applications for Jivi in the European Union and Japan.

Read the press release

Want to get news like this in your inbox?  Subscribe to our eNewsletter here!

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments